1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

Technology appraisal guidance [TA661] Published: 25 November 2020

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Tools and resources

Tools to help you put the guidance into practice.

Resource impact

  • Resource impact template Excel 1.46 MB 25 November 2020  
  • Resource impact report PDF 261 KB 25 November 2020  

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance